Previous 10 | Next 10 |
PHILADELPHIA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that two oral presentations and 11 posters across its develop...
Full-Year 2021 Galafold ® Revenue of ~$306M, Representing 17% YoY Growth Expect Double-Digit Growth (15-20%) of 2022 Galafold Revenue with $350M-$365M in Global Sales U.S. and EU Regulatory Reviews Underway for AT-GAA in Pompe Disease ...
PHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will present at the 40 th Annual J.P. Morgan Healthcare Conference, being held virtually on Wednesday, January 12, 2022 at 3:45 p.m. E.T. A live audio webcast of the ...
Amicus Therapeutics (NASDAQ:FOLD) announces that the EMA validated the Marketing Authorization Applications (MAA) for AT-GAA, an investigational two-component therapy for the treatment of Pompe disease, an inherited lysosomal disorder caused by deficiency of the enzyme acid alpha-glucosi...
PHILADELPHIA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA) for AT-GAA, the Company’s investigational two-component therapy for the treatment of Po...
PHILADELPHIA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4 th Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 1, 2021 at 8:50 a...
PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held virtually and in Sydney, Australia, November 21-23, 2021. ...
Peer Reviewed Results from PROPEL Show Treatment with AT-GAA Provided Clinically Meaningful Improvements Over Standard of Care, including ERT Experienced Patients with High Unmet Need AT-GAA Deemed to Provide a Differentiated Mechanism of Action and Potential Alternative Treatme...
We are circling back to Amicus Therapeutics today for the first time since this spring. The stock is trading near a longer-term floor, the company is moving toward profitability and has potential catalysts on the horizon. A full investment analysis is provided in the paragraphs be...
PHILADELPHIA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 8:00 a.m. E.T. A l...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K....